Clinical trials: Newly Diagnosed
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM)
18F-Fluciclovine PET/CT in Multiple Myeloma
Background: Multiple myeloma (MM) is an incurable cancer of certain blood cells. MM often returns after treatment, and most people survive only 5 to 8 years after diagnosis.
- Conditions
- Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Trial name
- NCT06103838
- Testing
- 18F-fluciclovine injection, 18F-FDG PET/CT
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Newly Diagnosed Glioblastoma, MGMT-Unmethylated Glioblastoma
A Single-Arm, Open-Label, Multicenter Clinical Study of Teniposide Combined With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (nGBM) With MGMT Promotor Region Unmethylated
The Primary Objective of this study is to evaluate the efficacy and safety of teniposide in combination with temozolomide for the treatment of newly diagnosed glioblastoma (nGBM) with MGMT promotor region unmethylated.
- Trial name
- NCT07894549
- Testing
- Teniposide Combined with Temozolomide
- Volunteers
- 72 people
- Sponsor
- Sun Yat-sen University
Glioblastoma (GBM), Newly Diagnosed Glioblastoma
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting.
- Conditions
- Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM)
- Trial name
- NCT07326566
- Testing
- silevertinib in combination with temozolomide, temozolomide (TMZ)
- Where
- 35 sites in United States
- Volunteers
- 162 people
- Sponsor
- Black Diamond Therapeutics, Inc.
Glioblastoma (GBM), High Grade Gliomas
Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
The goal of this clinical trial is to first define the Safety and Optimal Biological Dose (OBD) of study drug TGX-007 and to then further investigate the safety and efficacy in patients with newly diagnosed or recurrent…
- Conditions
- Glioblastoma (GBM), High Grade Gliomas, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
- Trial name
- ADePT (NCT07346144)
- Testing
- TGX-007, Valaciclovir
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 68 people
- Sponsor
- Trogenix ltd
Newly Diagnosed Multiple Myeloma (NDMM)
Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma
The goal of this clinical trial is to evaluate whether a modified (less frequent) dosing schedule of daratumumab, when added to standard VRd therapy, can be an effective induction regimen for treating newly diagnosed multiple…
- Trial name
- NCT07891923
- Testing
- Daratumumab (Intravenously) with VRd (Bortezomib, Lenalidomide, and Dexamethasone)
- Where
- 2 sites in India
- Volunteers
- 52 people
- Sponsor
- Tata Memorial Centre
Breast Cancer, Breast Cancer and Rehabilitation
Cancer Patient Navigation and Readiness
This study evaluated whether Cancer Patient Navigation (CPN) services could improve readiness for the transition from breast cancer diagnosis to treatment.
- Conditions
- Breast Cancer, Breast Cancer and Rehabilitation, Transition Care, Breast Cancer - Female
- Trial name
- CPN Readiness (NCT07892157)
- Testing
- Cancer Patient Navigation Services
- Where
- Indonesia
- Volunteers
- 64 people
- Sponsor
- Universitas Muhammadiyah Semarang
Breast Cancer Females, Newly Diagnosed Breast Cancer
Trial to Evaluate an Educational Video Series for Women in Breast Cancer Treatment
Approximately 200 English- or Spanish-speaking women newly diagnosed with stage I-III breast cancer will be randomized to either receive access to an online sexual health video series or receive usual care.
- Trial name
- NCT07434817
- Testing
- Sexual Health Educational Video Series, Standard Care (in control arm)
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- University of Colorado, Denver
Newly Diagnosed Multiple Myeloma (NDMM)
REAL World IMROZ OutcomEs (REALIZE Study)
Demonstrating the real-world effectiveness of Isa-VRD in routine NHS care is the key aim for this proposal Isatuximab (Isa) is an IgG1 monoclonal antibody that binds a specific epitope on the human CD38 receptor and has…
- Trial name
- REALIZE (NCT07889323)
- Volunteers
- 150 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Newly Diagnosed Multiple Myeloma (NDMM)
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
The purpose of this study is to measure the efficacy of AZD0120 compared with ASCT in terms of progression-free survival (PFS) according to the International Myeloma Working Group (IMWG) criteria 2016, and MRD negative complete…
- Trial name
- DURGA-6 (NCT07735637)
- Testing
- AZD0120, Cyclophosphamide, Fludarabine
- Where
- 114 sites in United States, Australia and 16 more
- Volunteers
- 750 people
- Sponsor
- AstraZeneca
Newly Diagnosed Multiple Myeloma
A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma
The goal of this clinical study iMMagine-4 is to compare and assess the safety and effectiveness of anitocabtagene autoleucel versus standard of care therapy (SOCT) in participants with newly diagnosed multiple myeloma (NDMM) who…
- Trial name
- iMMagine-4 (NCT07887672)
- Testing
- Anitocabtagene autoleucel, Daratumumab, Bortezomib
- Volunteers
- 600 people
- Sponsor
- Kite, A Gilead Company
Newly Diagnosed MGMT Unmethylated Glioblastoma
D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
The purpose of this research study is to determine the safety and efficacy of administering a single intracerebral (within the brain) dose of investigational compounds called D2C7-immunotoxin (IT) and 2141-V11 in residual disease…
- Trial name
- NCT05734560
- Testing
- D2C7-IT, 2141-V11
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Darell Bigner
Newly Diagnosed Glioblastoma, IDH-wildtype
Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma
This is an investigator-initiated, randomized, open-label, parallel-controlled clinical study designed to evaluate the efficacy and safety of locally administered Tris-CAR-T cells in adults with newly diagnosed glioblastoma.
- Trial name
- CAR-T (NCT07873996)
- Testing
- Tris-CAR-T cell injection, Ommaya reservoir implantation, Temozolomide (TMZ)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Tiantan Hospital
Hematological Patients, Newly Diagnosed Multiple Myeloma
Biomarkers in Multiple Myeloma
The association between multiple myeloma (MM) and venous thromboembolism (VTE) is well known. Indeed, the incidence of VTE is increased in patients with newly diagnosed MM and in patients treated by immunomodulatory drugs in…
- Conditions
- Hematological Patients, Newly Diagnosed Multiple Myeloma, Chemotherapy
- Trial name
- VESICOM (NCT05259553)
- Testing
- Blood samples
- Where
- 2 sites in France
- Volunteers
- 70 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Newly Diagnosed Triple-negative Breast Cancer
A Multicenter, Randomized, Controlled Phase III Clinical Trial on Adjuvant Intensified Therapy for Patients With Residual Disease After Neoadjuvant Treatment for Triple-negative Breast Cancer
This study is a multicenter, randomized controlled phase III clinical trial. The aim of this study is to observe the efficacy and safety of PD-1 inhibitors combined with capecitabine, PD-1 inhibitors alone, or capecitabine alone…
- Trial name
- CREATE (NCT07869628)
- Testing
- Capecitabine and PD-1 inhibitor, PD-1 inhibitor, Capecitabine
- Volunteers
- 852 people
- Sponsor
- Shandong Cancer Hospital and Institute
Newly Diagnosed Multiple Myeloma
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
This is a single center, open-label, phase 2 study in elderly (age ≥ 70) subjects with newly diagnosed multiple myeloma who are transplant ineligible.
- Trial name
- NCT04052880
- Testing
- Daratumumab, Bortezomib, Lenalidomide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Larysa Sanchez
Newly Diagnosed Cancer Patients
Smoking Cessation Intervention for Cancer Patients
The purpose of this study is to see if we can find ways to improve the treatment of tobacco dependence in patients who have cancer or may have cancer.
- Trial name
- NCT00575718
- Testing
- Hospital Counseling + Nicotine Replacement Therapy. questionaires, Hospital Counseling + Nicotine Replacement + Presurgical Scheduled Reduced Smoking, questionaires
- Where
- United States
- Volunteers
- 204 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
High Risk Newly Diagnosed Multiple Myeloma
Horizon Two: HR NDMM (MMRC-100)
The Multiple Myeloma Research Consortium (MMRC) Horizon Two trial is a master protocol, multi-center, phase II randomized adaptive platform trial designed to efficiently evaluate multiple investigational therapies in high-risk…
- Trial name
- NCT07053436
- Testing
- Bispecific Monoclonal Antibody and Triplet Therapy, Monoclonal Antibody with Stem Cell Transplant
- Where
- 12 sites in United States
- Volunteers
- 300 people
- Sponsor
- Multiple Myeloma Research Consortium
Newly Diagnosed Acute Myeloid Leukemia (AML)
Cardiotoxicity in Newly Diagnosed Acute Myeloid Leukemia Patients
The aim of this study is to evaluate and compare the cardiotoxic effects associated with anthracycline-based induction chemotherapy and those receiving a Venetoclax or HMA regimens after four cycles of chemotherpy in patients…
- Trial name
- AML/HMA (NCT07851012)
- Volunteers
- 146 people
- Sponsor
- Assiut University
Newly Diagnosed and Recurrent Glioblastoma
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
This study will investigate different doses of [177Lu]Lu-NeoB in combination with RT and TMZ in participants with newly diagnosed glioblastoma, with methylated or unmethylated promoter, to assess the safety and efficacy of…
- Trial name
- NCT05739942
- Testing
- [177Lu]Lu-NeoB, [68Ga]Ga-NeoB, Temozolomide
- Where
- 16 sites in United States, France and 4 more
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma, Newly Diagnosed
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
This study is designed as a multicenter, randomized, parallel groups, open-label, phase 3 study in subjects with untreated newly diagnoses Multiple Myeloma eligible for ASCT.
- Trial name
- ElLen (NCT06918002)
- Testing
- Elranatamab, Lenalidomide (Revlimid®), Daratumumab SC (Darzalex)
- Where
- 69 sites in Belgium, France
- Volunteers
- 824 people
- Sponsor
- Intergroupe Francophone du Myelome